Most material SEC filings — July 17, 2026

On July 13, 2026, Dare Bioscience received notice of failure to satisfy continued listing standards, triggering Item 3.01 disclosure of delisting risk or transfer of listing. No specific listing rule violation, remediation timeline, or details on which exchange are provided in the available filing text. The company trades at ~$21.3M market value.

On July 15, 2026, Actuate Therapeutics filed an 8-K disclosing Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, with potential transfer of listing. The filing document itself contains no specific details regarding which exchange issued the notice, which listing standard(s) were violated, cure periods, or remediation plans. Concrete counterparties, dollar amounts, dates of notice, or compliance metrics are absent from the available filing text.

Caring Brands, Inc. (market cap ~$4.0M) filed an 8-K on July 17, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard. The filing provides notice of a transfer of listing but does not disclose specific reasons, exchange name, timeline, remediation steps, or financial details in the extracted text.

Our Bond, Inc. registered 8,726,725 common shares issuable to Ascent Partners Fund LLC under an Equity Line SPA dated October 27, 2025 (amended), plus 1,203,275 shares upon conversion of Series G Convertible Preferred Stock held by Ascent. Combined, ~9.93M shares represent potential massive dilution for a company with $6.7M market cap. No pricing or timeline details disclosed in this legal opinion exhibit.

On July 14, 2026, Fold Holdings received a notice of delisting or failure to satisfy continued listing standards. The filing does not specify which exchange issued the notice, the specific listing rule violated, or remediation details. This represents a critical regulatory threat to the company's public market status.

On July 15, 2026, SOBR Safe (market cap ~$3.5M) announced exercise of 2,360,648 warrants (originally issued Dec 2025 at $1.30/share) for aggregate gross proceeds of $3.1 million. In consideration, the company issued Series E warrants (2,580,648 shares, $1.30 strike, 5-year term) and Series F warrants (2,140,648 shares, $1.30 strike, 24-month term). H.C. Wainwright Co. served as placement agent. The transaction closed July 17, 2026. Net proceeds will fund working capital and general corporate purposes.

Director SUMITOMO MITSUI FINANCIAL GROUP, INC. (JEF) bought 5.9M shares (~$318.7M) on the open market (41% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner PRUDENTIAL FINANCIAL INC (TYG) bought 6.0M shares (~$60.0M) on the open market (67% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Decisive Point Group, LLC (STDN) bought 17.9M shares (~$19.1M) on the open market (97% of holdings). Open-market insider purchase — historically a bullish signal.

Generation Income Properties amended Series B-1 (155,185 units held by LMB Owenton I LLC) and Series B-2 (698,465 units held by Lloyd M. Bernstein) Preferred Units effective July 16, 2026. The amendments eliminate holder-controlled cash redemption rights—valued at $7.15/unit for B-1 and $4.00/unit for B-2—and replace them with company-controlled optional exchanges into common stock at 1.0 exchange ratio. GIPR intends this to achieve permanent equity classification and satisfy Nasdaq's $2.5M stockholders' equity listing requirement by August 4, 2026.

Jet.AI completed its merger with flyExclusive on July 13, 2026, issuing 7,096,115 flyExclusive Class A shares (3.6253 exchange ratio per SpinCo share): 5,676,892 shares (80%, ~2.9002 ratio) issued immediately, 1,957,402 shares (20%, ~0.7251 ratio) held in reserve pending 90-day purchase price adjustment. Separately, on July 15, 2026, Jet.AI signed a non-binding LOI for a $300M reverse takeover (counterparty undisclosed), targeting ~$10/share additional value to Jet.AI shareholders and a combined entity valued at ~$320M, with planned close before year-end and a planned spin-off of data center assets into a separate public company (ticker DCTR reserved).

EisnerAmper LLP consented to inclusion of their August 15, 2025 audit report in BioVie's Form S-1 registration statement (filed ~July 17, 2026). The audit report explicitly contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern as of June 30, 2025 and 2024 year-ends.

Banzai International filed Form S-1/A on July 17, 2026 to register resale of 3,956,968 shares by holders of a $11M senior secured convertible note issued June 27, 2025 to an unnamed institutional investor. The resale shares comprise 2,309,107 conversion shares from the note plus 1,647,861 warrant shares. A 1-for-20 reverse stock split effective May 8, 2026 was retrospectively applied to all share counts.

Kalaris Therapeutics announced expanded Phase 1a SAD results for TH103 in neovascular AMD (17 treatment-naive + 3 treatment-experienced patients, all completed 6-month follow-up). Key findings: mean 9.2-letter BCVA improvement at Month 1; 27–53× lower plasma Cmax than leading anti-VEGF agents; 29% of patients required no retreatment over 6 months, 41% not retreated until ≥4 months. Safety: no IOI cases at 2.5 mg with manufacturing batch #2; one transient IOI at 5 mg. Phase 1b/2 enrollment ongoing; preliminary data expected 1H 2027; cash runway extends to Q4 2027.

Rhinebeck Bancorp completed an oversubscribed conversion of its mutual holding company (Rhinebeck Bancorp, MHC) to stock form on July 21, 2026. Eligible depositors' subscription orders exceeded the offering maximum, triggering allocation procedures. Post-conversion, the company will have 15,638,237 shares outstanding; existing shareholders receive 1.3978 new shares per old share, with fractional shares paid at $10.00/share. The ESOP will purchase up to 4% of offered shares in the open market post-closing.

CO2 Energy Transition Corp. (Nasdaq: NOEM), a blank-check SPAC with ~$70.7M market value, signed a non-binding Letter of Intent with an unnamed Texas-based oil and gas company to recover lithium and strontium ferrite from subsurface brines for defense applications. The parties aim to negotiate definitive agreements by September 16, 2026. No financial terms, valuation, or deal size disclosed; transaction remains subject to due diligence, definitive agreements, and regulatory approvals.

GoodVision AI signed a strategic cooperation agreement with AI Storm Co., Ltd. (Tokyo Stock Exchange: 3719) to develop AI infrastructure in Japan. Phase 1 (3 months): Deploy 2 MW Fukushima facility with 72 NVIDIA B300 servers and 500+ GPUs. Phases 2–3 target 20 MW within 12 months and 100 MW within 3 years across Japan, with 50+ reserved sites. GoodVision is merging with Calisa Acquisition Corp (Nasdaq: ALIS) via Business Combination Agreement, expected to close in H2 2026.

Grayscale Avalanche Staking ETF (assets ~$5.3M) amended its trust agreement (Amendment No. 2, dated 2026) to formally permit staking of AVAX tokens held in the trust, provided the "Staking Condition" is satisfied. The amendment mandates quarterly distribution of staking rewards to shareholders and requires compliance with SEC guidance (Statement on Certain Staking Activities, May 29, 2025) and IRS Revenue Procedure 2025-31. However, the filing extensively disclaims that grantor trust tax status—critical to shareholder taxation—remains uncertain and unconfirmed by the IRS; loss of grantor status could trigger entity-level 21% taxation and materially reduce shareholder returns.

enGene Therapeutics disclosed interim data from its pivotal LEGEND Phase 2 cohort (N=125, BCG-unresponsive high-risk NMIBC with CIS) showing 54% complete response (CR) at any time, with low dose interruption (2.4%) and discontinuation (2.4%) rates. The company holds $285M cash and expects to file a BLA in 2H 2026, with potential FDA approval and platform designation in 2027. A surfactant bladder rinse formulation is in development with preclinical data suggesting 9-10x improved IL-12 expression and efficacy.

On April 30, 2026, Exodus Movement, Inc. completed acquisition of Monavate Holdings Limited (UK payment processor) and related entities for total consideration of $131.7M, comprising $5.0M cash at closing, $19.8M fair value of deferred payments over four years, and $106.9M in loan forgiveness (W3C Loans: $76.2M principal+interest; Howat Loans: $10.2M forgiven). Monavate generated £61.5M revenue and £8.2M net loss in 2025; pro forma combined entity shows $152.8M revenue and $53.6M net loss for 2025, with $96.0M goodwill recognized.

Effective July 15, 2026, AO Partners I, L.P. and its general partner AO Partners, LLC transferred sole voting and investment power over 31,931 shares of Air T common stock to Rick D. Leggott, a member/investor in the fund. The shares represent Leggott's pro rata interest in the fund's Air T holdings. The agreement permits annual or semi-annual adjustment of share count to track Leggott's indirect equity stake, with 61-day termination notice required.

Alpha Modus Holdings filed Form S-1 on July 17, 2026, to register up to 4,000,000 shares of Class A common stock ($0.0001 par) for sale by Streeterville Capital, LLC under a Securities Purchase Agreement dated June 29, 2026. The offering comprises 3,550,000 pre-paid purchase shares and 1,250,000 pre-delivery shares already issued to Streeterville. Counsel opinion confirms shares are validly authorized and will be fully paid and non-assessable.

President and CEO BOUDREAUX GAIL (ELV) bought 3K shares (~$1.0M) on the open market (1.6% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Aqua Capital, Ltd. (ENR) bought 80K shares (~$1.7M) on the open market (1.0% of holdings). Open-market insider purchase — historically a bullish signal.

Insider STRACKE THIBAULT CHRISTIAN (PDI) bought 100K shares (~$1.6M) on the open market (36% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Chairman FRIES MICHAEL T (LILA) bought 155K shares (~$1.0M) on the open market (96% of holdings). Open-market insider purchase — historically a bullish signal.

Director Batista de Lima Filho Pedro (AXIA3) bought 210K shares (~$2.0M) on the open market (13% of holdings). Open-market insider purchase — historically a bullish signal.